12:00 AM
 | 
Nov 09, 2009
 |  BC Week In Review  |  Company News  |  Deals

Zhejiang Tianyuan, Novartis deal

Novartis agreed to acquire an 85% stake in vaccine company Zhejiang Tianyuan for RMB850 million ($124.5 million) in cash. Tianyuan has marketed vaccines for seasonal influenza, hemorrhagic fever with renal syndrome, Japanese encephalitis and meningococcal meningitis. According to Novartis, Tianyuan had 2008 sales of $25...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >